1-(2-乙基丁基)-哌啶 | 91249-15-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(2-乙基丁基)-哌啶
• 英文名称: 1-Piperidino-2-aethyl-butan
• 英文别名: 1-(2-ethyl-butyl)-piperidine；1-(2-Ethylbutyl)piperidine
• CAS: 91249-15-9
• 化学式: C₁₁H₂₃N
• 分子量: 169.31
• InChiKey: CQVFIGINRWUUHW-UHFFFAOYSA-N

物化性质

• 沸点：
  81 °C(Press: 12 Torr)
• 密度：
  0.840±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  哌啶 、 反-2-戊烯 、 一氧化碳 在 Rh(IMes)(cod)Cl 、 氢气 作用下， 以 四氢呋喃 为溶剂， 85.0 ℃ 、6.0 MPa 条件下， 反应 12.0h， 生成 1-(2-乙基丁基)-哌啶 、 1-(2-甲基戊基)哌啶
  参考文献：
  名称：

  Hydroaminomethylation of olefins using a rhodium carbene catalyst

  摘要：

  Hydroaminomethylation of terminal as well as internal aliphatic and aromatic olefins with various amines is described in the presence of [Rh(cod)(Imes)Cl] as a catalyst. In general good to excellent yields and high chemo selectivity were obtained in THF at 85-105degreesC using 0.1 mol% of catalyst. (C) 2003 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(03)00008-x

文献信息

• Highly Selective Hydroaminomethylation of Internal Alkenes To Give Linear Amines
  作者：Moballigh Ahmed、Raymond P. J. Bronger、Ralf Jackstell、Paul C. J. Kamer、Piet W. N. M. van Leeuwen、Matthias Beller

  DOI：10.1002/chem.200600702

  日期：2006.12.4

  internal olefins and mixtures of internal and terminal olefins have been converted highly selectively into linear amines. Investigations of the effects of the calculated natural bite angles of ligands on hydroaminomethylation shows that the regioselectivity for the linear product follows a similar trend to that seen in the hydroformylation of internal alkenes with the aid of these ligands. Hydroaminomethylation

  据报道，苯氧磷膦改性的Xantphos型配体（1-9）在铑催化的内烯烃加氢氨基甲基化反应中得到线性胺。通过使用0.1摩尔％[Rh（cod）2] BF（4）/0.4摩尔％黄嘌呤草磷（1）获得了出色的化学和区域选择性，为从内部制备胺提供了实用且对环境有吸引力的合成途径烯烃。第一次，官能化的内烯烃以及内烯烃和末端烯烃的混合物都被高度选择性地转化为线性胺。对所计算的配体的自然咬合角对氢氨基甲基化的影响的研究表明，线性产物的区域选择性遵循与借助这些配体的内部烯烃的氢甲酰化所观察到的趋势相似的趋势。通过高压红外光谱法监测氢氨基甲基化及其各个步骤。结果表明，氢氨基甲基化通过顺序异构化/加氢甲酰化/胺化/加氢途径发生。
• 1,4-DISUBSTITUTED 1,2,3-TRIAZOLES, METHODS FOR PREPARING SAME, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
  申请人：Routier Sylvain

  公开号：US20140030191A1

  公开（公告）日：2014-01-30

  A compound having the following general formula (I): wherein: X is a nitrogen atom and Y is a carbon atom; or X is a carbon atom and Y is a nitrogen atom; the Ar group is an aryl or heteroaryl group; and the RN and RN′ groups, together with the carbon atoms to which they are bound, form a monocyclic or bicyclic azacycloalkane group. The pharmaceutically acceptable salts thereof, the hydrates or polymorphic crystalline structures thereof, and to the racemates, diastereoisomers, or enantiomers thereof are also described.

  具有以下通式（I）的化合物：其中：X是氮原子，Y是碳原子；或者X是碳原子，Y是氮原子；Ar基团是芳基或杂芳基；RN和RN′基团，与其所连接的碳原子一起，形成单环或双环氮杂环烷基团。还描述了其药学上可接受的盐、水合物或多晶型晶体结构，以及其消旋体、非对映异构体或对映异构体。
• HIV REPLICATION INHIBITING PYRIMIDINES
  申请人：Janssen Pharmaceutica NV

  公开号：EP3808743A1

  公开（公告）日：2021-04-21

  This invention concerns HIV replication inhibitors of formula the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a1=a2-a3=a4- and -b1=b2-b3=b4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl;n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; substituted C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; substituted Cl-6alkyloxyCl-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)pR6, -NH-S(=O)pR6, -C(=O)R6, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6, -C(=NH)R6 or a 5-membered heterocycle; X1 is -NR5-, -NH-NH-, -N=N-, -O-, -C(=O)-, C1-4alkanediyl, -CHOH-, -S-, -S(=O)p-, -X2-C1-4alkanediyl- or -C1-4alkanediyl-X2-; R3 is NHR13; NR13R14; -C(=O)-NER13; -C(=O)-NR13R14; -C(=O)-R15; -CH=N-NH-C(=O)-R16; substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl; substituted C2-6alkynyl; C1-6alkyl substituted with hydroxy and a second substituent; -C(=N-O-R8)-C1-4alkyl; R7; or -X3-R7; R4 is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl)amino; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.

  本发明涉及式中的艾滋病毒复制抑制剂 的N-氧化物、药学上可接受的加成盐、季胺及其立体异构体形式，其中含有-a1=a2-a3=a4-和-b1=b2-b3=b4-的环代表苯基、吡啶基、嘧啶基、吡嗪基、哒嗪基；取代的C1-6烷氧基Cl-6烷基羰基；R2 是羟基、卤代、任选取代的 C1-6 烷基、C3-7 环烷基、任选取代的 C2-6 烯基、任选取代的 C2-6 烷炔基、C1-6烷氧基、C1-6烷氧基羰基、羧基、氰基、硝基、氨基、单或双（C1-6烷氧基羰基）、C1-6烷氧基羰基、C1-6烷基羧基、C1-6烷基羰基氨基、单-或二(C1-6烷基)氨基、多卤甲基、多卤甲基氧基、多卤甲基硫代、-S(＝O)pR6、-NH-S(＝O)pR6、-C(＝O)R6、-NHC(＝O)H、-C(＝O)NHNH2、-NHC(＝O)R6、-C(＝NH)R6 或 5 元杂环；X1 是-NR5-、-NH-NH-、-N=N-、-O-、-C(=O)-、C1-4烷二基、-CHOH-、-S-、-S(=O)p-、-X2-C1-4烷二基-或-C1-4烷二基-X2-； R3 是 NHR13；NR13R14；-C(=O)-NER13；-C(=O)-NR13R14；-C(=O)-R15；-CH=N-NH-C(=O)-R16；取代的 C1-6 烷基；任选取代的 C1-6 烷氧基 C1-6 烷基；取代的 C2-6 烯基；取代的 C2-6 烷炔基；被羟基和第二个取代基取代的 C1-6 烷基；-R4为卤代、羟基、C1-6烷基、C3-7环烷基、C1-6烷氧基、氰基、硝基、多卤代C1-6烷基、多卤代C1-6烷氧基、氨基羰基、C1-6烷氧基羰基、C1-6烷基羰基、甲酰基、氨基、单-或二(C1-4烷基)氨基；它们的医药用途、制备工艺和包含它们的药物组合物。
• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20170158683A1

  公开（公告）日：2017-06-08

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
• US9611260B2
  申请人：——

  公开号：US9611260B2

  公开（公告）日：2017-04-04